518P - Feasibility and outocome of adult patients with osteosarcoma of the jaws. A single institute experience-

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Bone Sarcomas
Presenter Yu Oshiro
Citation Annals of Oncology (2016) 27 (suppl_9): ix163-ix168. 10.1093/annonc/mdw597
Authors Y. Oshiro, T. Shimoi, H.S. Okuma, A.K. Kawai, A. Shimomura, E. Noguchi, M. Yunokawa, C. Shimizu, K. Yonemori, Y. Fujiwara, K. Tamura
  • Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP



Osteosarcoma of the jaws is very rare, accounting for only 6% to 7% of all osteosarcomas. It is treated with the same high intensity as that of osteosarcomas of the long bones, although it has a different biological behavior with a lower incidence of metastases and a better prognosis. Also, adults are known to have a lower feasibility of intensive chemotherapy compared to children. We performed a retrospective study to examine the feasibility and outcome of adult patients with osteosarcoma of the jaws.


Consecutive patients with high-grade osteosarcoma of the jaw treated with perioperative Meyer’s MAP (high-dose methotrexate; HD-MTX, doxorubicin; DXR, and cisplatin; CDDP) regimen at our department. Clinicopathological characteristics were reviewed from the medical charts. Relative dose intensity (RDI) of MAP and factors associated with the RDI were analyzed.


A total of five patients underwent surgical resection and received MAP in the perioperative period. Median age was 28 (range; 24-43). Median follow-up time was 20.9 months. Three patients are relapse-free and two patients had recurrences after or during chemotherapy. The accomplish rate of full schedule MAP was 0%. RDI of HD-MTX, DXR and CDDP were 52%, 78% and 89%, respectively. Average RDI of MAP was 73%. The factors related to low RDI were acute renal failure, liver dysfunction and delayed clearance of methotrexate.


MAP for adult osteosarcoma of the jaws was difficult to control adverse events and complete chemotherapy. Although survival is not available in this data, in the case of osteosarcoma of the jaws, by lowering dose intensity of chemotherapy, improvement of tolerability can be expected. Further investigation is needed.

Clinical trial indentification

Legal entity responsible for the study

National Canceer Center Hospital


National Canceer Center Hospital


All authors have declared no conflicts of interest.